Marion Lenoir1,2, Silvina Del Carmen3, Naima G Cortes-Perez4,5, Daniel Lozano-Ojalvo4,5,6, Diego Muñoz-Provencio1,2, Florian Chain1,2, Philippe Langella1,2, Alejandra de Moreno de LeBlanc3, Jean Guy LeBlanc7, Luis G Bermúdez-Humarán8,9. 1. INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, 78350, Jouy-en-Josas, France. 2. AgroParisTech, UMR1319 Micalis, 78350, Jouy-en-Josas, France. 3. Centro de Referencia para Lactobacilos (CERELA-CONICET), T4000ILC, San Miguel de Tucumán, Argentina. 4. INRA, UR496 Unité d'Immuno-Allergie Alimentaire, Jouy-en-Josas, France. 5. CEA, IBiTecS, Service de Pharmacologie et d'Immunoanalyse, Gif-sur-Yvette, France. 6. Instituto de Investigación en Ciencias de la Alimentación (CIAL, CSIC-UAM), Madrid, Spain. 7. Centro de Referencia para Lactobacilos (CERELA-CONICET), T4000ILC, San Miguel de Tucumán, Argentina. leblanc@cerela.org.ar. 8. INRA, Commensal and Probiotics-Host Interactions Laboratory, UMR 1319 Micalis, 78350, Jouy-en-Josas, France. luis.bermudez@jouy.inra.fr. 9. AgroParisTech, UMR1319 Micalis, 78350, Jouy-en-Josas, France. luis.bermudez@jouy.inra.fr.
Abstract
BACKGROUND: Chronic intestinal inflammation alters host physiology and could lead to colorectal cancer (CRC). We have previously reported beneficial effects of the probiotic strain of Lactobacillus casei BL23 in different murine models of intestinal inflammation. In addition, there is an emerging interest on the potential beneficial effects of probiotics to treat CRC. We thus explored whether L. casei BL23 displays protective effects on CRC. METHODS: Mice were subcutaneously injected with 1,2-dimethylhydrazine (DMH) weekly during 10 weeks and orally administered with L. casei BL23 in the drinking water until the 10th week. Multiple plaque lesions in the large intestine were observed macroscopically and counted and intestinal tissues were also histologically analyzed. Finally, T-cell populations and cytokine production were evaluated after co-incubation of L. casei BL23 with spleen cells from non-treated mice to determine the immuno-modulatory effects of this bacterium. RESULTS: Our results show that oral treatment with this probiotic bacterium modulates host immune responses and significantly protect mice against DMH-induced CRC. This protection may be associated with the modulation of regulatory T-cells towards a Th17-biased immune response accompanied by the expression of regulatory cytokines (IL-6, IL-17, IL-10 and TGF-β), as demonstrated in L. casei BL23-treated splenocytes, but also with the colonic expression of IL-22 observed in vivo on L. casei BL23-treated mice; suggesting the induction of a fine-tune Th17-biased response. CONCLUSIONS: Altogether our results reveal the high potential of L. casei BL23 to treat CRC and opens new frontiers for the study of immunomodulatory functions of probiotics.
BACKGROUND:Chronic intestinal inflammation alters host physiology and could lead to colorectal cancer (CRC). We have previously reported beneficial effects of the probiotic strain of Lactobacillus casei BL23 in different murine models of intestinal inflammation. In addition, there is an emerging interest on the potential beneficial effects of probiotics to treat CRC. We thus explored whether L. casei BL23 displays protective effects on CRC. METHODS:Mice were subcutaneously injected with 1,2-dimethylhydrazine (DMH) weekly during 10 weeks and orally administered with L. casei BL23 in the drinking water until the 10th week. Multiple plaque lesions in the large intestine were observed macroscopically and counted and intestinal tissues were also histologically analyzed. Finally, T-cell populations and cytokine production were evaluated after co-incubation of L. casei BL23 with spleen cells from non-treated mice to determine the immuno-modulatory effects of this bacterium. RESULTS: Our results show that oral treatment with this probiotic bacterium modulates host immune responses and significantly protect mice against DMH-induced CRC. This protection may be associated with the modulation of regulatory T-cells towards a Th17-biased immune response accompanied by the expression of regulatory cytokines (IL-6, IL-17, IL-10 and TGF-β), as demonstrated in L. casei BL23-treated splenocytes, but also with the colonic expression of IL-22 observed in vivo on L. casei BL23-treated mice; suggesting the induction of a fine-tune Th17-biased response. CONCLUSIONS: Altogether our results reveal the high potential of L. casei BL23 to treat CRC and opens new frontiers for the study of immunomodulatory functions of probiotics.
Entities:
Keywords:
Colorectal cancer; Lactic acid bacteria; Lactobacillus casei BL23; Probiotics
Authors: Caspar Ohnmacht; Joo-Hong Park; Sascha Cording; James B Wing; Koji Atarashi; Yuuki Obata; Valérie Gaboriau-Routhiau; Rute Marques; Sophie Dulauroy; Maria Fedoseeva; Meinrad Busslinger; Nadine Cerf-Bensussan; Ivo G Boneca; David Voehringer; Koji Hase; Kenya Honda; Shimon Sakaguchi; Gérard Eberl Journal: Science Date: 2015-07-09 Impact factor: 47.728
Authors: Elias Gounaris; Nichole R Blatner; Kristen Dennis; Fay Magnusson; Michael F Gurish; Terry B Strom; Philipp Beckhove; Fotini Gounari; Khashayarsha Khazaie Journal: Cancer Res Date: 2009-07-01 Impact factor: 12.701
Authors: Alejandra de Moreno de LeBlanc; Jean Guy LeBlanc; Gabriela Perdigón; Anderson Miyoshi; Philippe Langella; Vasco Azevedo; Fernando Sesma Journal: J Med Microbiol Date: 2008-01 Impact factor: 2.472
Authors: S Hazebrouck; L Przybylski-Nicaise; S Ah-Leung; K Adel-Patient; G Corthier; P Langella; J-M Wal Journal: Vaccine Date: 2009-08-03 Impact factor: 3.641
Authors: V De Simone; E Franzè; G Ronchetti; A Colantoni; M C Fantini; D Di Fusco; G S Sica; P Sileri; T T MacDonald; F Pallone; G Monteleone; C Stolfi Journal: Oncogene Date: 2014-09-01 Impact factor: 9.867
Authors: Cesar Antonio Irecta-Nájera; María Del Rosario Huizar-López; Josefina Casas-Solís; Patricia Castro-Félix; Anne Santerre Journal: Probiotics Antimicrob Proteins Date: 2017-06 Impact factor: 4.609
Authors: Elsa Jacouton; Florian Chain; Harry Sokol; Philippe Langella; Luis G Bermúdez-Humarán Journal: Front Immunol Date: 2017-11-17 Impact factor: 7.561
Authors: A Paula Domínguez Rubio; Jimena H Martínez; Diana C Martínez Casillas; Federico Coluccio Leskow; Mariana Piuri; Oscar E Pérez Journal: Front Microbiol Date: 2017-09-20 Impact factor: 5.640